Back to Newsroom

Corbus Pharmaceuticals Receives FDA Clearance to Initiate Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, life-threatening chronic inflammatory and fibrotic diseases, announced today that its Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) is now open and the Company is authorized to initiate a Phase 2 clinical study with Resunab™ for the treatment of cystic fibrosis (“CF”). Corbus expects to initiate a Phase 2 clinical study with Resunab in adults with CF within the next 90 days.

Click here to read more